Innoviva (INVA) Goodwill & Intangibles (2013 - 2026)
Innoviva posted quarterly Goodwill & Intangibles of $193.5 million for Q1 2026, down 30.79% year-on-year from $279.6 million in Q1 2025, and down 3.28% on a QoQ basis from $200.1 million in Q4 2025.
Innoviva (INVA) has 7 years of Goodwill & Intangibles data on file, last reported at $193.5 million in Q1 2026.
- For the quarter ending Q1 2026, Goodwill & Intangibles fell 30.79% year-over-year to $193.5 million; the trailing twelve-month figure through Mar 2026 stood at $193.5 million (down 30.79% YoY), and the FY2025 full-year result was $200.1 million, down 11.61% from the prior year.
- Goodwill & Intangibles for Q1 2026 stood at $193.5 million, down from $200.1 million in the prior quarter.
- Across five years, Goodwill & Intangibles topped out at $285.2 million in Q4 2022 and bottomed at $105.0 million in Q2 2022.
- The 5-year median for Goodwill & Intangibles is $241.8 million (2024), against an average of $232.5 million.
- The widest annual swing landed in 2023, when Goodwill & Intangibles jumped 159.62%; it then tumbled 30.79% in 2026.
- A 5-year view of Goodwill & Intangibles shows it stood at $285.2 million in 2022, then dropped by 3.37% to $275.6 million in 2023, then slipped by 17.87% to $226.3 million in 2024, then slipped by 11.61% to $200.1 million in 2025, then declined by 3.28% to $193.5 million in 2026.
- The last three Goodwill & Intangibles figures came in at $193.5 million (Q1 2026), $200.1 million (Q4 2025), and $279.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 193.50 Mn |
| Dec 31, 2025 | 200.06 Mn |
| Sep 30, 2025 | 279.61 Mn |
| Jun 30, 2025 | 213.32 Mn |
| Mar 31, 2025 | 279.61 Mn |
| Dec 31, 2024 | 226.34 Mn |
| Sep 30, 2024 | 228.84 Mn |
| Jun 30, 2024 | 235.36 Mn |
| Mar 31, 2024 | 241.80 Mn |
| Dec 31, 2023 | 275.60 Mn |
| Sep 30, 2023 | 254.75 Mn |
| Jun 30, 2023 | 272.60 Mn |
| Mar 31, 2023 | 276.26 Mn |
| Dec 31, 2022 | 285.20 Mn |
| Sep 30, 2022 | 274.49 Mn |
| Jun 30, 2022 | 105.00 Mn |
| Mar 31, 2022 | 110.54 Mn |
| Sep 30, 2014 | 211.65 Mn |
| Jun 30, 2014 | 194.88 Mn |
| Mar 31, 2014 | 137.48 Mn |
| Dec 31, 2013 | 124.26 Mn |
| Sep 30, 2013 | 40.00 Mn |
| Jun 30, 2013 | 30.00 Mn |